Who is most likely to benefit from deep brain stimulation for psychiatric disorders?

Who benefits most from deep brain stimulation for psychiatric disorders?

The strongest evidence points to patients with severe, treatment-resistant disorders—those who have not responded to multiple medications or therapies. In a recent NIH-funded study of Tourette syndrome, 4 out of 8 patients (50%) who received chronic responsive DBS met the primary outcome of at least a 30% reduction in tic severity on the Yale Global Tic Severity Scale [1]. For epilepsy, a separate study found that 54.5% of patients were responders, with an average seizure reduction of 73.6% [3]. These figures show that about half of carefully selected patients can achieve meaningful improvement, but the other half do not—highlighting that DBS is not a universal solution.

For depression and OCD, the evidence is less clear-cut but still promising. A 2023 review notes that DBS for these conditions is transitioning from empiricism to science-driven approaches, with advances in neuroimaging and neurophysiology improving outcomes [7]. A personalized approach using intracranial recordings to tailor stimulation parameters led to remission in the first treated patient with treatment-resistant depression in a double-blind, randomized phase [4]. This suggests that patients who undergo individualized targeting and programming may benefit more than those receiving standard settings.

How much improvement can patients expect, and what are the risks?

Improvement varies by condition and individual. In the Tourette syndrome study, responders saw at least a 30% reduction in tic severity, but the study also noted that 50% of patients did not meet this threshold [1]. In the epilepsy study, responders averaged a 73.6% seizure reduction, but non-responders actually experienced an average seizure increase of 27.3% [3]. This underscores that DBS can worsen symptoms in some patients, so careful patient selection is critical.

Side effects are a real concern. In the epilepsy study, 5 out of 13 patients (38.5%) experienced intolerable side effects, mostly psychiatric, and 8 of 22 active electrodes (36.4%) were off-target, which may have contributed to these issues [3]. For Parkinson's disease, a randomized trial found that DBS improved quality of life, mood, and anxiety, but also caused small declines in some cognitive tests, such as the Stroop III (a measure of executive function) [2]. These findings mean that while DBS can be life-changing for some, it carries risks of cognitive or psychiatric worsening that must be weighed against potential benefits.

Under what conditions does DBS work best?

Precise electrode placement is crucial. In the epilepsy study, when patients with both electrodes off-target were removed from the analysis, the responder rate dropped from 54.5% to 44.4% [3]. This suggests that accurate targeting directly impacts success. Similarly, the personalized approach for depression used intracranial recordings to optimize stimulation parameters, leading to remission [4]. This indicates that individualized programming—rather than one-size-fits-all settings—may be key.

The type of DBS also matters. Responsive (closed-loop) DBS, which delivers stimulation only when abnormal brain activity is detected, showed proof of concept in Tourette syndrome, with 50% of patients responding [1]. This approach may reduce side effects by avoiding continuous stimulation. However, a 2023 review notes that in psychiatry, symptom changes take days to weeks to appear, making it harder to find optimal settings compared to Parkinson's disease, where changes are immediate [5]. This means that patients and clinicians need patience and a systematic approach to programming.

Finally, DBS is currently only appropriate for patients with severe, treatment-resistant disorders who have exhausted other options. Researchers unanimously agree that DBS should not be used for enhancement (e.g., mood or cognitive boosting) in healthy individuals until brain target localization and functioning are better understood [6]. The risk-benefit ratio is very different for diseased versus non-diseased individuals, so DBS remains a last-resort therapy for psychiatric conditions.

About These Sources

This answer is built on 7 peer-reviewed studies — published from 2021 to 2024, 1 from 2024 or later, 6 in Q1 journals, collectively cited 299 times — selected as the most relevant from 8 studies that passed quality screening, drawn from 76 papers retrieved from a database of over 500 million.

Sources used in this answer

Related research questions